Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash Flows From Operating Activities
Net (loss) income	$ (18,522)	$ 18,779	$ (47,896)
Adjustments to reconcile net (loss) income to net cash and cash equivalents provided by (used in) operating activities:
Stock-based compensation	29,344	20,652	14,599
Deferred taxes	(21,913)	(11,740)	(15,253)
Depreciation and amortization	67,731	59,791	59,653
Unrealized gain on investment in equity securities	(6,307)	0	0
Acquired in-process research and development ("IPR&D")	0	0	1,151
Non-cash operating lease expense	1,526	1,269	0
Non-cash interest	642	3,922	3,961
Contingent consideration fair value adjustment	(619)	1,426	4,058
Gain on sale of building	(5,347)	0	0
Loss on extinguishment of debt	7,468	0	0
Amortization of inventory step up	13,599	0	0
Asset impairment charges	7,600	0	574
Gain on sale of ANDAs	0	0	(750)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable, net	(21,087)	3,359	(36,912)
Inventories	(21,287)	(5,841)	(23,626)
Prepaid expenses and other assets	2,129	(9,015)	(798)
Accounts payable	479	7,552	5,038
Accrued royalties	6,350	6,969	3,082
Income taxes	(1,415)	11,991	(160)
Accrued government rebates	6,160	1,296	5,380
Returned goods reserve	9,102	(3,722)	(2,399)
Accrued expenses, accrued compensation, and other	8,384	12,271	(905)
Net Cash and Cash Equivalents Provided by (Used in) Operating Activities	64,017	118,959	(31,203)
Cash Flows From Investing Activities
Acquisition of product rights, intangible assets, and other related assets	(717)	(9,643)	(7,579)
Acquisition of property and equipment, net	(16,236)	(8,868)	(8,876)
Proceeds from the sale of long-lived assets	0	0	750
Proceeds from the sale of building	13,514	0	0
Net Cash and Cash Equivalents Used in Investing Activities	(404,719)	(18,511)	(15,738)
Cash Flows From Financing Activities
Proceeds from convertible notes	316,250	0	0
Proceeds from term loan	325,000	0	0
Purchase of capped call transaction	(40,575)	0	0
Proceeds from public offering	0	80,555	0
Payments on contingent consideration	(12,500)	(12,500)	0
Principal payments on borrowings under credit agreements	(3,531)	(3,000)	(3,000)
Debt issuance costs	(17,353)	0	0
Repayment on borrowings under credit agreement	(292,500)	0	0
Payment of accrued licensor payment	(3,750)	0	0
Series A convertible preferred stock dividends paid	(1,625)	(1,625)	(1,625)
Proceeds from stock option exercises and ESPP purchases	6,488	8,996	1,458
Treasury stock purchases for restricted stock vests	(10,959)	(4,987)	(1,959)
Net Cash and Cash Equivalents Provided by (Used in) Financing Activities	264,945	67,439	(5,126)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	(470)	0	0
Net Change in Cash, Cash Equivalents, and Restricted Cash	(76,227)	167,887	(52,067)
Cash and cash equivalents, beginning of year	221,121	53,234	105,301
Cash, cash equivalents and restricted cash, end of year	144,894	221,121	53,234
Reconciliation of cash, cash equivalents, and restricted cash, beginning of year
Cash and cash equivalents	144,861	221,121	48,228
Restricted cash	33	0	5,006
Total cash, cash equivalents, and restricted cash	144,894	221,121	53,234
Supplemental disclosure for cash flow information:
Cash paid for interest, net of amounts capitalized	24,379	31,431	21,477
Cash paid for income taxes	19,061	1,228	288
Right-of-use assets obtained in exchange for lease obligations	0	4,715	0
Supplemental non-cash investing and financing activities:
Purchase consideration for Alimera Acquisition	(8,322)	0	0
Acquisition of product rights included in accounts payable	0	0	1,000
Property and equipment purchased and included in accounts payable	529	328	452
Alimera
Cash Flows From Investing Activities
Acquisition of Novitium Pharma LLC, net of cash acquired	(401,280)	0	0
Novitium Pharma LLC
Cash Flows From Investing Activities
Acquisition of Novitium Pharma LLC, net of cash acquired	$ 0	$ 0	$ (33)